BioSpace News Archive

According to the latest market report published by Persistence Market Research, titled ‘Global Wireless Fetal Monitoring System: Industry Analysis (2013-2017) and Forecast (2018-2026)’, the global wireless fetal monitoring system is expected to expand at a CAGR of 6.8% during the forecast period 2018–2026. The wireless fetal monitoring systems is segmented based on product type, application, end user and region.

Arthritis Research Canada/Arthrite-recherche Canada is collaborating with the COVID-19 Global Rheumatology Alliance on an international initiative collecting information on rheumatology patients with COVID-19 from around the world.

InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,715,240 shares of its common stock at a purchase price of $1.75 per share in a registered direct offering priced at-the-market under Nasdaq rules

Vir Biotechnology, Inc. (NASDAQ: VIR) today announced additional interim data from the ongoing Phase 2 trial in patients and results from the Phase 1 trial in healthy volunteers of VIR-2218, an investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi) for the treatment of chronic hepatitis B virus (HBV) infection.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received loan proceeds of $3,191,700 (“PPP Loan”) under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times the average monthly payroll expenses of the qualifying business, calculated as provided under the P

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Northwell Health’s research arm, The Feinstein Institutes for Medical Research , today announced enrollment of the first patient in Vanda’s clinical trial, ODYSSEY VLY-686-3501 (NCT04326426), yesterday at Lenox Hill Hospital in New York City . ODYSSEY is a Phase III double

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that due to the COVID-19 pandemic and to support the health and safety of the company’s stockholders, employees, Board of Directors and surrounding communities, Gilead’s 2020 Annual Meeting of Stockholders will be held in a virtual-only format instead of as an in-person meeting. In light of this change, stockholders will not be able to attend the Annual Meeting in person.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of the CALYPSO program to study the role that human genetic variations play in SARS-CoV-2 (“COVID-19") infection and disease progression.

New treatments designed to prevent cancer from developing, based on changing the microenvironment in which cancer cells evolve, could be both feasible and effective.

According to the latest market report published by Persistence Market Research, titled ‘Global Ambulance Stretchers Market: Global Industry Analysis 2013 – 2017 and Forecast 2018 – 2026’, the Global Ambulance Stretchers market is expected to expand at a CAGR of 2.2% over the forecast period 2018–2026.